Monoclonal antibodies for treatment of cancer
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-039/395
C07K-016/30
C12N-005/20
C07K-016/46
C12N-005/16
C12N-015/113
A61K-039/00
출원번호
US-0636277
(2011-03-10)
등록번호
US-9216218
(2015-12-22)
우선권정보
EP-10003082 (2010-03-23)
국제출원번호
PCT/EP2011/001198
(2011-03-10)
§371/§102 date
20121204
(20121204)
국제공개번호
WO2011/116885
(2011-09-29)
발명자
/ 주소
Sahin, Ugur
Tureci, Ozlem
Koslowski, Michael
Mitnachtkraus, Rita
출원인 / 주소
GANYMED PHARMACEUTICALS AG
대리인 / 주소
McAndrews Held & Malloy, Ltd.
인용정보
피인용 횟수 :
3인용 특허 :
36
초록▼
The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing GT468, including tumor-related diseases such as breast cancer, lung cancer, gastric cancer, ovarian cancer, hepatocellular cancer, colon cancer, pancreatic cancer
The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing GT468, including tumor-related diseases such as breast cancer, lung cancer, gastric cancer, ovarian cancer, hepatocellular cancer, colon cancer, pancreatic cancer, esophageal cancer, head & neck cancer, kidney cancer, in particular renal cell carcinoma, prostate cancer, liver cancer, melanoma, sarcoma, myeloma, neuroblastoma, placental choriocarcinoma, cervical cancer, and thyroid cancer, and the metastatic forms thereof. In one embodiment, the tumor disease is metastatic cancer in the lung.
대표청구항▼
1. An isolated antibody that binds human GT468 selected from the group consisting of: (i) an antibody comprising six complementarity determining regions (CDRs), wherein said antibody is produced by a hybridoma deposited under the accession number DSM ACC3039 (4A5 1E11 1B7), DSM ACC3037 (7H12 2E6 2C4
1. An isolated antibody that binds human GT468 selected from the group consisting of: (i) an antibody comprising six complementarity determining regions (CDRs), wherein said antibody is produced by a hybridoma deposited under the accession number DSM ACC3039 (4A5 1E11 1B7), DSM ACC3037 (7H12 2E6 2C4), DSM ACC3036 (11 D7 1G10 2B4), DSM ACC3038 (18-2A-1), DSM ACC3040 (63-1A-2), or DSM ACC3042 (3E5 2G4),(ii) a chimerized or humanized antibody comprising the six CDRs of the antibody under (i), and(iii) an antibody comprising the six complementarity determining regions (CDRs) of the antibody under (i). 2. A hybridoma deposited under the accession number DSM ACC3039 (4A5 1E11 1B7), DSM ACC3037 (7H12 2E6 2C4), DSM ACC3036 (11 D7 1G10 2B4), DSM ACC3038 (18-2A-1), DSM ACC3040 (63-1A-2), or DSM ACC3042 (3E5 2G4). 3. A conjugate comprising an isolated antibody of claim 1 coupled to a therapeutic agent. 4. The conjugate of claim 3 wherein the therapeutic agent is a toxin, a radioisotope, a drug or a cytotoxic agent. 5. A pharmaceutical composition comprising an isolated antibody of claim 1 and/or a conjugate of claim 3 or 4, and a pharmaceutically acceptable carrier. 6. An isolated host cell capable of expressing a chimerized or a humanized antibody that binds human GT468 comprising the six complementarity determining regions (CDRs) of an antibody produced by the hybridoma of claim 2.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (36)
Presta Leonard G. ; Snedecor Bradley R., Altered polypeptides with increased half-life.
Ladner Robert C. (Iamsville MD), Computer based system and method for determining and displaying possible chemical structures for converting double- or m.
Winter Gregory Paul (Cambridge GB3) Duncan Alexander Robert (Wimbledon GBX) Burton Dennis Raymond (Sheffield GB3), DNA encoding antibodies with altered effector functions.
Ladner Robert C. (Ijamsville MD) Bird Robert E. (Rockville MD) Hardman Karl (Chevy Chase MD), Immunotheraphy using single chain polypeptide binding molecules.
La Zor Clair G. (13054 Rose St. Cerritos CA 90701), Instrument for locating faults in aircraft passenger reading light and attendant call control system.
Low Philip S. (West Lafayette IN) Horn Mark A. (West Lafayette IN) Heinstein Peter F. (West Lafayette IN), Method for enhancing transmembrane transport of exogenous molecules.
Loughrey Helen C. (Vancouver CAX) Cullis Pieter R. (Vancouver CAX) Bally Marcel B. (Bowen Island CAX) Choi Lewis S. (Burnaby CAX), Method for protein-liposome coupling.
Fanger Michael W. (Lebanon NH) Guyre Paul M. (Hanover NH) Anderson Clark L. (Columbus OH), Monoclonal antibodies to FC receptors for immunoglobulin G on human mononuclear phagocytes.
McKinnon ; Jr. Charles N. (Laguna Niguel CA) Peterson Steven F. (West Linn OR) Smith Paul E. (Tualatin OR) Nakagawa Takaaki (Tigard OR) Bartholomew Victor L. (Tigard OR), Needleless hypodermic injection device.
Peterson Steven F. (West Linn OR) McKinnon ; Jr. Charles N. (Laguna Niguel CA) Smith Paul E. (Tualatin OR) Nakagawa Takaaki (Tigard OR) Bartholomew Victor L. (Tigard OR), Needleless hypodermic injection methods and device.
Venter, J. Craig; Zhang, Jinghui N.; Liu, Xiangjun; Rowe, William; Cravchik, Anibal; Kalush, Francis; Naik, Ashwinikumar; Subramanian, Gangadharan; Woodage, Trevor, Polymorphisms in known genes associated with human disease, methods of detection and uses thereof.
Huston James S. (Newton MA) Charette Marc F. (West Roxbury MA) Cohen Charles M. (Medway MA) Crea Roberto (Boston MA) Keck Peter C. (Millbury MA) Oppermann Hermann (Medway MA) Rueger David C. (West Ro, Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage.
Eppstein Deborah A. (Los Altos CA) Fraser-Smith Elizabeth B. (Los Altos CA) Matthews Thomas R. (Los Gatos CA), Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.